Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

HC Wainwright issued their Q1 2025 earnings estimates for shares of Jazz Pharmaceuticals in a research note issued to investors on Monday, March 10th. HC Wainwright analyst O. Livnat forecasts that ...

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th.

Limited or Ligand Pharmaceuticals Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In our opinion, the deal is a strategic fit for Jazz Pharmaceuticals, which currently markets five oncology drugs, namely Defitelio, Vyxeos, Rylaze, Zepzelca and Ziihera. The addition of Chimerix ...

Jazz Pharmaceuticals JAZZ has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...

Limited or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' ...

Jazz Pharmaceuticals plc’s revenues continue to benefit from strong demand for newer drugs like Xywav, Epidiolex and Rylaze. Sales of the epilepsy drug Epidiolex are being driven by geographic ...